Navigation Links
Drug shown to improve memory in those with Down syndrome
Date:7/17/2012

AURORA, Colo. (July 17, 2012) Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life.

"Before now there had never been any positive results in attempts to improve cognitive abilities in persons with Down syndrome through medication," said Alberto Costa, MD, Ph.D., who led the four- year study at the CU School of Medicine. "This is the first time we have been able to move the needle at all and that means improvement is possible."

The study was published today in the journal Translational Psychiatry.

Costa, an associate professor of medicine, and his colleagues studied 38 adolescents and young adults with Down syndrome. Half took the drug memantine, used to treat Alzheimer's disease, and the others took a placebo.

Costa's research team hypothesized that memantine, which improved memory in mice with Down syndrome, could increase test scores of young adults with the disorder in the area of spatial and episodic memory, functions associated with the hippocampus region of the brain.

Participants underwent a 16-week course of either memantine or a placebo while scientists compared the adaptive and cognitive function of the two groups.

While they found no major difference between the groups in adaptive and most measures of cognitive ability, researchers discovered that those taking memantine showed significant improvement in verbal episodic memory. One of the lowest functioning individuals in the study saw a ten-fold increase in memory skills.

"People who took the medicine and memorized long lists of words did significantly better than those who took the placebo," said Costa, a neuroscientist specializing in Down syndrome research. "This is a first step in a longer quest to see how we can improve the quality of life for those with Down syndrome."
'/>"/>

Contact: Jacque Montgomery
jacque.montgomery@ucdenver.edu
303-928-9093
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Facial defects shown to self-repair
2. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
3. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
4. Clinical insight improves treatment with new lung cancer drug
5. Improved Stem Cell Line May Avoid Tumor Risk: Study
6. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
7. Exercise improves quality of life during breast cancer treatment
8. IU, Regenstrief automated system aims to improve child health
9. Swallowing exercises linked with short-term improvement among patients with head and neck cancer
10. MU receives national award for using mind-body approach to improve health
11. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
(Date:7/25/2014)... July 25, 2014 Parker Waichman LLP, ... of consumers comments on a recent tobacco lawsuit in ... smoker $23.6 billion in punitive damages. Cynthia Robinson brought ... cigarettes. The case is Cynthia Robinson v. R.J. Reynolds ... Florida First Circuit Court, Escambia County, Florida; Case Number ...
(Date:7/25/2014)... Drexel University College of Medicine is pleased ... been appointed vice dean for education, effective October 1, 2014. ... Medical College, where she is currently chair of the Department ... of medicine. , As a member of the senior ... major role in many aspects of the development of the ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
(Date:7/25/2014)... 25, 2014 The new report ... Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, ... Geography - Global Trends & Forecasts to 2019", ... of the global Carbohydrase market with analysis of ... is segmented and values are forecasted on the ...
Breaking Medicine News(10 mins):Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4
... Universal Capital Management, Inc. (OTC Bulletin Board: ... provides management and strategic growth resources to emerging ... of its holdings, iVolution Medical Systems, Inc., recently ... service company located in New York City, New ...
... Tamiflu in stock for consumers who do not yet have the ... required, patients must provide their health information and medical history before ... 1-800-467-0297. Patients should not take Tamiflu until flu symptoms are ... ...
... will add several new core and elective clinical rotations at Danbury Hospital ... ... 2009-- Ross University School of Medicine is pleased to announce it will ... of clinical rotations on the East Coast. The new placements will be ...
... and controversial policy change made by Blue Cross Blue Shield of Massachusetts ... venous community--from patients to physicians to the businesses that provide vein-related goods ... ... of mid April, 2009, BCBS has mandated that in the state of ...
... RIO DE JANEIRO, Brazil, May 12 Amilpar ... the largest managed care organization in Brazil, announced today its ... At the end of March, total membership ... 2.3% down on the 3.18 million recorded in the 4Q08.Adjusted ...
... The American College of Medical Genetics (ACMG) has ... American Pathologists, and the American Society for Clinical Pathology ... the human genes associated with breast and ovarian cancer ... options regarding their health care. The lawsuit challenges patents ...
Cached Medicine News:Health News:iVolution Medical Systems Acquires Continental Collection Services 2Health News:AccessRx.com Provides Same-Day Shipping for Tamiflu, an Effective Treatment for Swine Flu 2Health News:Ross University School of Medicine Expands Clinical Rotations on East Coast 2Health News:Blue Cross/Blue Shield Of Massachusetts Introduces Controversial Criteria For Vein Treatment Reimbursement 2Health News:Blue Cross/Blue Shield Of Massachusetts Introduces Controversial Criteria For Vein Treatment Reimbursement 3Health News:Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009 2Health News:ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics 2Health News:ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics 3
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Minn., Oct. 7 Prime Therapeutics (Prime) announces that it ... of Care. Wickersham will manage Prime,s Clinical and ... medical and pharmacy. In this role, he will be responsible ... breakthrough results for Prime and its clients. "Keeping ...
... MINNEAPOLIS, Oct. 7 Nonin Medical, Inc., a ... today the release of its second-generation wrist-worn pulse ... PureSAT® SpO2 technology, the WristOx2, Model 3150 is ... proven accuracy in the widest range of clinical ...
Cached Medicine Technology:Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care 2Nonin Medical Announces Its Second-Generation Wrist-Worn Device for European Distribution: Delivering Reliability in the Widest Range of Patient Populations and Clinical Settings 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... test face is used to evaluate both low ... (high, 25% and 12.5%) of LogMAR acuity (20/16 ... as well as the two spatial frequencies of ... widely used for cataract documentation because eye doctors ...
... The CSV-1000RS test face is used widely ... presents ETDRS LogMAR acuity from 20/10 to ... at 12 cycles/degree. , ,The patient can ... for ETDRS acuity and contrast sensitivity. If ...
... monza is the latest addition to the ... It is a compact, semi-automated clinical analyser ... RX monza is a complete clinical analyser ... Designed for straightforward operation and consistent performance, ...
Medicine Products: